Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target hoisted by Royal Bank of Canada from $402.00 to $407.00 in a research note issued to investors on Tuesday,Benzinga reports.

Fintel reports that on February 12, 2025, Canaccord Genuity upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

UnitedHealth reported fourth-quarter adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72.

One headwind that could slow the uptake of the Vertex pain drug, though, is cost. The list price is $15.50 per pill ... opioid if given the choice. Vertex stock today trades for about 24x forward ...

Vertex's stock price has shown resilience, with a year-to-date performance of +22% as of September 2024. This growth has positioned the company as a potential value name in the biotech sector, ...

Morgan Stanley upped their target price on shares of Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th.

The American oil refining company Vertex Energy Inc. filed for bankruptcy in the US Bankruptcy Court in Texas a few months after the suspension of production of renewable diesel fuel at the refinery ...